$1.2M AHRQ Grant to Study the Power of Prediction
Associate professor Jessica Keim-Malpass has earned a $1.2 million R01 grant from the Agency for Research and Quality (AHRQ) to continue her work to assess and integrate predictive monitoring software into hospital intensive care units to inform the care of acutely ill patents suffering from cardiological problems.
$1.2MKeim-Malpass's new three-year AHRQ grant
The new three-year AHRQ grant—"Predictive monitoring: IMPact of real-time predictive monitoring in acute care cardiology trial (PM-IMPACCT)"—supports Keim-Malpass's randomized controlled trial that will evaluate the impact of predictive analytics monitoring on improvement in patient outcomes, response time to proactive clinical action, and costs to the healthcare system.
Keim-Malpass's team includes UVA School of Medicine colleague Jamie Bourque as well as UVA public health scientists Sarah Ratcliffe and Tanya Wancheck.
- [read] "How UVA created artificial intelligence to watch over patients with COVID-19" (UVA Today, January 2021)
- [listen] "UVA's early warning system for COVID-19 patients" (WVTF/NPR, January 2021)
- [watch] "Meet Betty Irene Moore Nurse Leader and Innovator Jessica Keim-Malpass" (UCDavis Health, September 2021)
- [read] "Visual Metaphors" (VNL, fall 2018)
Keim-Malpass—also a National Academy of Medicine Scholar in Diagnostic Excellence, a Betty Irene Moore Fellow, and a Costs of Care Fellow alumna. who has also earned funding from the National Science Foundation and the National Institutes of Health, among other organizations—studies the use and deployment of predictive analytics in acutely ill and vulnerable patient populations, healthcare economics, and health policy.
A pediatric nurse practitioner and a professor of pediatrics in UVA's School of Medicine, the work is a continuation and expansion of an effort she first undertook with UVA cardiologist Randall Moorman on the novel CoMET software, which uses continuous monitoring to assess COVID patients' trajectories and create an image of risk and future decompensation.
Keim-Malpass and her team expect to have preliminary results this November/December.